Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

Login or register to view PDF.
Creative Commons Licence
Received date
13 May 2020
Accepted date
13 May 2020
European Cardiology Review 2020;15:e31.
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Aims: To assess the clinical and neurohormonal characteristics of patients eligible to sacubitril/valsartan (SV) attending to an outpatient heart failure clinic and describe variables related to SV prescription in real-life heart failure patients.

Design and methods: We collected data from 119 consecutive patients attending our heart failure outpatient clinic between May 2018 and November 2018.

Results: 75.5% of the patients were men. At baseline, mean age was 64 ± 10 years; mean LVEF was 28 ± 6%; 42% had ischaemic aetiology; and 83 patients (70%) were New York Heart Association (NYHA) class II. Median NT-proBNP was 1,288 pg/ml (IQR 377–3,967), mean glomerular filtration rate (GFR) 67.0 ± 22.8 ml/min and potassium was 4.5 ± 0.4 mEq/l. The majority (85%) of patients were treated with ACE inhibitors or angiotensin receptor blockers, while 96% received beta-blockers and 86% mineralocorticoid receptor antagonists. Of 119 eligible patients, 64 (53.8%) were treated with SV. Achieving >50% of beta-blocker target dose, GFR ≥ 60 ml/min and systolic blood pressure (SBP) ≥110 mmHg were significantly associated with the prescription of SV. In a multivariate analysis adjusted for age and beta-blocker dose, a higher systolic blood pressure (SBP; OR 1.26 95% CI [1.16–2.01]) and GFR (OR 1.02, 95% CI [1.01–1.14]) were independently associated with the prescription of SV.

Conclusion: The rate of prescription of SV in our cohort is relatively higher than in other real-life registries. Low SBP and GFR suggest a subgroup of patients with a higher risk of adverse events, requiring an optimisation of concomitant treatment, mainly diuretics and vasodilators, leading to a higher rate of SV prescription.